In Segment A, individuals will acquire various doses and schedules of oral ABBV-744 tablet to detect Risk-free dosing program. More participants is going to be enrolled at the recognized monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be supplied as "incorporate-on" therapy. In https://theodorem776yjv9.mappywiki.com/user